Ftse Mib
33.541,98
-0,49%
DAX
18.155,24
-0,04%
S&P 500
5.477,90
0,16%
NASDAQ
17.805,16
0,49%
Bitcoin
60.958,29
0,24%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cellectis SA (CLLS) Cellectis SA (CLLS) Notizie

CLLS

Cellectis (CLLS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CLLS
DataOraFonteTitoloSimboloCompagnia
20/06/202422:30GlobeNewswire Inc.Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base EditingNASDAQ:CLLSCellectis SA
12/06/202422:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
12/06/202422:30GlobeNewswire Inc.Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature CommunicationsNASDAQ:CLLSCellectis SA
04/06/202422:30GlobeNewswire Inc.Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic LeukemiaNASDAQ:CLLSCellectis SA
29/05/202422:30GlobeNewswire Inc.Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024NASDAQ:CLLSCellectis SA
28/05/202422:30GlobeNewswire Inc.Cellectis Reports Financial Results for First Quarter 2024NASDAQ:CLLSCellectis SA
27/05/202422:30GlobeNewswire Inc.Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024NASDAQ:CLLSCellectis SA
06/05/202408:00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaNASDAQ:CLLSCellectis SA
02/05/202422:30GlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerNASDAQ:CLLSCellectis SA
29/04/202422:46GlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:CLLSCellectis SA
22/04/202422:30GlobeNewswire Inc.Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsNASDAQ:CLLSCellectis SA
10/04/202422:30GlobeNewswire Inc.Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsNASDAQ:CLLSCellectis SA
08/04/202422:30GlobeNewswire Inc.Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingNASDAQ:CLLSCellectis SA
16/01/202422:30GlobeNewswire Inc.Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)NASDAQ:CLLSCellectis SA
22/12/202322:30GlobeNewswire Inc.Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023NASDAQ:CLLSCellectis SA
17/11/202322:30GlobeNewswire Inc.Cellectis’ Shareholders Meeting to be Held on December 22, 2023NASDAQ:CLLSCellectis SA
15/11/202308:30GlobeNewswire Inc.Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZenecaNASDAQ:CLLSCellectis SA
06/11/202322:30GlobeNewswire Inc.Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023NASDAQ:CLLSCellectis SA
02/11/202321:30GlobeNewswire Inc.Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual MeetingNASDAQ:CLLSCellectis SA
01/11/202321:30GlobeNewswire Inc.Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023NASDAQ:CLLSCellectis SA
01/11/202320:15AllPennyStocks.comBiotech Shares Soar After AstraZeneca Stake & Research CollaborationNASDAQ:CLLSCellectis SA
01/11/202312:52Dow Jones NewsCellectis Shares Soar Premarket on AstraZeneca DealNASDAQ:CLLSCellectis SA
01/11/202309:17Dow Jones NewsAstraZeneca to Invest $245 Million in Deal With CellectisNASDAQ:CLLSCellectis SA
01/11/202308:00GlobeNewswire Inc.Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZenecaNASDAQ:CLLSCellectis SA
31/10/202322:10Edgar (US Regulatory)Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]NASDAQ:CLLSCellectis SA
31/10/202321:30GlobeNewswire Inc.Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingNASDAQ:CLLSCellectis SA
12/10/202322:30GlobeNewswire Inc.Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)NASDAQ:CLLSCellectis SA
27/09/202322:30GlobeNewswire Inc.Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingNASDAQ:CLLSCellectis SA
05/09/202322:32Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:CLLSCellectis SA
07/08/202323:05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CLLSCellectis SA
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CLLS

La tua Cronologia

COIN
TBTOEUR
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network